Improvement of Asia-Pacific Colorectal Screening score and evaluation of its use combined with fecal occult blood test

CURRENT STATUS: ACCEPTED

Xuxia He
Peking Union Medical College Hospital

Siyi Yuan
Peking Union Medical College Hospital

Wenbin Li
Peking Union Medical College Hospital

Hong Yang
Peking Union Medical College Hospital

Wen Ji
Peking Union Medical College Hospital

Zhiqiang Wang
Peking Union Medical College Hospital

Jianyu Hao
Beijing Chaoyang Hospital

Chuan Chen
University of Hong Kong

Weiqing Chen
Chongqing University

Yingxin Gao
Beijing Chaoyang Hospital

Lingbo Li
Nantong University

Kaifeng Cheng
| CHINESE ACADEMY OF MEDICAL SCIENCES AND PEKING UNION MEDICAL COLLEGE |
|---------------------------------------------------------------|
| Jiaming Qian                                                  |
| Peking Union Medical College Hospital                        |
| Li Wang                                                       |
| Chinese Academy of Medical Sciences and Peking Union Medical College |
| JN Li                                                         |
| Peking Union Medical College Hospital                        |

**Corresponding Author**
hexvxia@163.com
ORCiD: https://orcid.org/0000-0002-9218-6409

**DOI:**
10.21203/rs.2.14962/v1

**SUBJECT AREAS**
*Gastroenterology & Hepatology*

**KEYWORDS**
*Colorectal cancer screening; Advanced colorectal neoplasia; Predictive model; Immunochemical fecal occult blood test; High risk population*
Abstract

Background

The Asia-Pacific Colorectal Screening (APCS) score is effective to screen high-risk groups of advanced colorectal neoplasia (ACN) patients but needs revising and can be combined with the fecal occult blood test (FOBT). This paper aimed to improve the APCS score and evaluate its use with the FOBT in stratifying the risk of ACN.

Methods

This prospective and multicenter study enrolled 955 and 1201 asymptomatic Chinese participants to form the derivation and validation set, respectively. Participants received the risk factor questionnaire, colonoscopy and immunochemical FOBT. Multiple logistic regression was applied, and C-statistic, sensitivity and negative predictive values (NPVs) were used to compare the screening efficiency.

Results

A modified model was developed incorporating age, body mass index (BMI), family history, diabetes, smoking and drinking as risk factors, stratifying subjects into average risk (AR) or high risk (HR). In the validation set, the HR tier group had a 3.4-fold (95% CI 1.8-6.4) increased risk for ACN. The C-statistic for the modified score was 0.69 ± 0.04, and 0.67 ± 0.04 for the original score. The sensitivity of the modified APCS score combined with FOBT for screening ACN high-risk cohorts was 76.7% compared with 36.7% of FOBT alone and 70.0% of the modified APCS score alone. The NPVs of the modified score combined with FOBT for ACN were 98.0% compared with 97.0% of FOBT alone and 97.9% of the modified APCS score alone.

Conclusions

The modified score and its use with the FOBT are efficient in selecting the HR group from a Chinese asymptomatic population.

Introduction

Colorectal cancer (CRC) is the fourth leading malignant tumor for incidence and the second most common for mortality in both sexes across the world based on the 2018 GLOBOCAN estimates[1], and
the morbidity of CRC in the Chinese population has continued to rise in recent years\textsuperscript{[2]}. CRC screening, including the fecal occult blood test (FOBT) and colonoscopy, has been shown to effectively reduce the prevalence of colorectal neoplasia and increase survival\textsuperscript{[3–5]}. Guidelines generally recommend that CRC screening should be carried out in people aged over 50 years via FOBT, including guaiac-based (gFOBT) and immunochemical (FIT), or endoscopy, including colonoscopy or sigmoidoscopy\textsuperscript{[6]}, which is hindered to some extent in China due to the large population and limited medical resources. It’s reported that the FOBT is relatively cost-effective and annual FOBT can reduce CRC mortality by approximately 30\textsuperscript{[7, 8]}, but the effect is achieved in prerequisite that positive FOBT be followed by more expensive tests, including colonoscopy. Therefore, it is important to develop a simple predictive model that can be used to screen high-risk (HR) groups of CRCs to make subsequent screening methods, mainly colonoscopy, more effective and targeted. Moreover, due to the cost-effectiveness of FOBT, the risk score can be combined with FOBT to achieve a higher level of screening efficiency.

The Asia-Pacific Colorectal Screening (APCS) score was established via the study of a derivation set of 860 subjects and a validation set of 1892 subjects\textsuperscript{[9]}. Nevertheless, the original APCS model is relatively simple and is based merely on elementary clinical data, including sex, age, family history and smoking status. Other risk factors, such as diabetes mellitus\textsuperscript{[10]}, alcohol consumption\textsuperscript{[11]} and obesity\textsuperscript{[12]}, were overlooked, although they have been reported to be closely related to CRC in previous studies. In addition, the original APCS score overlooked the significance of FOBT in current CRC screening and failed to test the combination of the score with FOBT. Therefore, our team hoped to further improve the original APCS score model by adding other risk factors to make it more comprehensive and effective and investigate the validity of the combined use of the modified score and FOBT.

Based on a list of CRC-related risk factors, including sex, age, smoking status, alcohol consumption, diabetes, family history, obesity, diet and exercise, this study aimed to improve the existing APCS score and validate the modified model to confirm its effectiveness in screening high-risk groups of
CRC among a Chinese asymptomatic population and further test the validity of the score combined with FOBT.

Methods

2.1 Study aims

The purpose of this study was three-fold. First, it aimed to improve the original APCS score as a risk-prediction model for ACN screening in an asymptomatic Chinese population. Second, it was intended to validate the effectiveness of the modified score for clinical use in a larger population and third, to compare its efficiency with FOBT for screening ACN high-risk cohorts.

2.2 Study participants

We prospectively enrolled 955 participants to form the derivation set in 3 hospitals (Peking Union Medical College Hospital, Beijing Chaoyang Hospital and Beijing Friendship Hospital) from September 2016 to December 2017. Then, a modified screening score can be conducted based on the analysis of data from the derivation set. Afterwards, 1201 participants were enrolled in the same way into the validation set in 5 hospitals (Peking Union Medical College Hospital, Chongqing Cancer Hospital, Chinese PLA General Hospital, Beijing Chaoyang Hospital and The University of Hong Kong-Shenzhen Hospital) from January 2018 to December 2018. All participants were outpatients over 40 years old who were asymptomatic and agreed to join the study. Those with a medical history of colorectal cancer, colorectal polyps or inflammatory bowel disease, or with colonoscopy contraindications were excluded.

2.3 Study design, ethical approval and consent to participate

This prospective, multicenter, large-scale study was conducted in asymptomatic Chinese subjects based on questionnaires, FOBT, colonoscopy findings and statistical analysis. This study was approved by the Ethical Committee of Peking Union Medical College Hospital, and the registration number on “Chinese Clinical Trial Registry” was ChiCTR-SOD-16008774. All participants signed informed consent before enrollment in this study.

2.4 Questionnaire and colonoscopy

All participants in the derivation set and the validation set filled out the risk factor questionnaire and
underwent colonoscopy. Considering the possible risk factors of ACN, we designed the questionnaire to collect basic demographic variables and certain personal information incorporating age, sex, height, weight, family history of CRC in a first-degree relative, smoking status, alcohol consumption, diet preference, exercise habits, and diabetes mellitus. Questionnaires were made simple to boost patient cooperation as much as possible. Alcohol consumption was defined as an intake of 150 g ethanol or more per week. Regular exercise required working out at least 3 times per week and 30 minutes every time. Height, weight and diabetes mellitus were self-reported. Diet preference was defined as vegetable-based, meat-based, or mixed food. All questionnaires were completed by eligible subjects with the assistance of medical staff and trained volunteers.

Standardized colonoscopy was conducted by experienced endoscopists in a double-blinded way at all study sites. The withdrawal observation time was ≥6 minutes to minimize the possibility of false negative results under the requirements of the international standard of quality assurance for colonoscopy procedures. Colorectal neoplasia includes nonadvanced adenoma and advanced colorectal neoplasia (ACN). ACN was defined as CRC or advanced adenoma. Advanced adenoma was defined as adenomas ≥10 mm in diameter, villous histological features (at least 25% villous), high-grade dysplasia, or any combination thereof.

Additionally, immunochemical FOBT (WHPM Bioresearch and Technology Co., Ltd) was conducted in part of the validation cohort for better evaluating the screening efficiency for ACN in combination with the modified risk score. The cutoff value of 0.2 μg Hb/mL feces was defined for FIT positivity in our study. Of note, only part of the validation set received FOBT because not all hospitals adopted immunochemical FOBT and part of the outpatient participants failed to offer stool samples.

2.5 Sample size estimation

In our study, the prevalence of ACN in the derivation set was 4.1%. The reported prevalence of ACN in Asia was between 3% and 12%[13–15]. According to these data, at least 1200 asymptomatic subjects were needed in the validation set to achieve the power of 80% at p<0.05.

2.6 Statistical analysis

All statistical analyses were conducted with SPSS software (version 25.0). Percentages were reported
as proportions and 95% confidence intervals (CIs). Continuous variables were expressed as the mean ± standard deviation (SD). The statistical review of the study was performed by a biomedical statistician.

Risk factors were analyzed by the Pearson chi-square test. The risk factors with a P value of ≤0.15 were selected for multivariate logistic regression analysis. The risk score was developed through the analysis of odds ratio (OR), the Hosmer-Lemeshow goodness-of-fit statistic, the C-statistic and area under receiver operating characteristic (ROC). The sensitivity and negative predictive values (NPVs) of the modified APCS score combined with FOBT for screening high-risk cohorts for colonoscopy were thereafter compared. The number needed to screen (NNS) for detecting one advanced neoplasia was calculated.

Results

3.1 Characteristics of the participants

The derivation set and the validation set comprised 955 and 1201 participants, respectively (Table 1). A total of 197 (20.6%) subjects in the derivation set were diagnosed with colorectal neoplasia by colonoscopy, including 34 (3.6%) cases of advanced adenoma and 5 (0.5%) cases of colorectal cancers. Moreover, the validation set was composed of 383 (31.9%) cases of colorectal neoplasia, including 35 (2.9%) cases of advanced adenoma and 10 (0.8%) cases of cancers. The baseline prevalence of ACN in the two sets was 4.1% and 3.7%, respectively. In terms of FOBT, there were a total of 742 subjects that received the test, including 117 (15.8%) positive cases. The distribution of all these factors in the two cohorts is shown in Table 1, and Figure 1 is a flowchart demonstrating the process of the validation set.

3.2 Univariate and multivariate predictors of colorectal neoplasia and advanced neoplasia in the derivation cohort

We performed univariate and multivariate analyses for each risk factor in the derivation set (Table 2). For ACN, age (59–69 or ≥70 years), smoking, alcohol consumption, diabetes, BMI (≥23 [16]) and family history of CRC in a first-degree relative were significant factors, with ORs (95% CI) of 1.4 (0.7–3.0) or 5.2 (1.8–15.1), 2.4 (1.2–4.5), 2.0 (1.0–4.0), 3.9 (1.5–10.7), 2.2 (1.0–4.8), and 2.3 (1.0–5.4),
respectively. Further, in multivariate analyses, these factors still reached significance, with ORs (95% CI) of 2.9 (1.4–6.1) or 9.8 (3.4–28.2), 1.8 (0.8–3.8), 2.1 (0.9–4.9), 3.5 (1.2–9.9), 2.1 (0.9–4.9), and 2.5 (1.0–6.1), respectively (Table 2). The Hosmer-Lemeshow goodness-of-fit statistic was p = 0.93 for the derivation cohort.

3.3 Development of the risk score

We incorporated age, family history of first-degree relatives, smoking, alcohol consumption, diabetes and BMI into the risk score model for ACN with points weighted based on adjusted ORs from the multiple logistic regression. Each adjusted OR was rounded to appropriate integers to simplify the score as much as possible and increase the feasibility.

The final score model is shown in Table 3. The total score of the risk model is 12, with points assigned as follows: age <59 (0), 59–69 (2), or ≥70 (5); family history absent (0) or present (2); never smoked (0) or current or past smoker (1); never drank (0) or current or past drinker (1); diabetes absent (0) or present (2); BMI < 23 (0) or ≥ 23 (1). Through a comprehensive analysis of the ROC curve, Youden’s index and Euclidean’s index, we artificially defined two risk tiers: 0–2 as average risk (AR), and ≥3 as high-risk (HR). Among the derivation cohort, 541 (56.6%) and 414 (43.4%) were in the AR and HR tiers, respectively (Table 4). The C-statistic in the derivation set was 0.74 ± 0.04.

3.4 Validation of the risk score model

Based on the adjusted risk score, 743 (61.9%) subjects in the validation set were classified as the AR tier (score 0–2), while 458 (38.1%) were classified as the HR tier (score ≥3). The prevalence of ACN in the AR and HR categories were 2.0% (95% CI 1.0%–3.0%) and 6.6% (95% CI 4.3%–8.8%), respectively (P<0.001). The HR cohort showed a 3.4-fold (95% CI 1.8–6.4) increased risk compared to the AR cohort for ACN, and similarly, 3.1 (95% CI 2.4–4.0) for colorectal neoplasia and 3.8 (95% CI 1.0–14.9) for CRC (Table 4). The C-statistic for the modified score predicting ACN was 0.69 ± 0.04, compared with 0.67 ± 0.04 for the original APCS score. The Hosmer-Lemeshow goodness-of-fit statistic was 0.87 in the validation cohort. Furthermore, the number needed to screen (NNS) for detecting one advanced neoplasia was 23.

3.5 Comparison with FOBT
In the validation set, a total of 742 subjects received FOBT, and the distribution of FOBT results combined with the above risk score tiers are listed in Table 5. The combined risk score and FOBT positive screening were defined as FOBT positive or classified into HR score tier; the combined screening negative was defined as FOBT negative in AR group. Thus, the sensitivity of the modified APCS score combined with FOBT for screening ACN high-risk cohorts for colonoscopy was 76.7% compared with 36.7% of FOBT alone and 70.0% of the modified score alone, indicating that the screening efficiency of the combined method was better than that of the score or FOBT alone. The tendency was similar for advanced adenoma, CRC, and nonadvanced neoplasia screening. Moreover, NPVs of the modified score combined with FOBT were 98.0% compared with 97.0% of FOBT alone and 97.9% of the modified APCS score alone, with the slight difference similar for other categories of colorectal diseases (Table 5).

**Discussion**

Effective screening methods, principally referring to FOBT and colonoscopy, can reduce the prevalence and mortality of CRCs. However, standardized and effective CRC screening strategies cannot be carried out across China, mainly due to resource limitations and lack of health awareness, leading to the urgency for more efficient and targeted primary screening schedules. Under such conditions, the economical and simple risk score system or its combined use with FOBT are attracting an increasing level of interest in the world. Some studies\(^\text{[17–19]}\) have attempted to establish a screening questionnaire model for a high-risk group of CRCs that is generally not comprehensive and short of feasibility. The APCS system established by scholars from the Chinese University of Hong Kong\(^\text{[20]}\) considered risk factors including sex, age, family history and smoking status and has been validated by different studies in various parts of Asia-Pacific area and even in Western countries\(^\text{[21–29]}\). However, the APCS score failed to collect information on the height and weight of participants, so it was impossible to judge the role of BMI in the prediction system. In addition, the original score failed to take FOBT, which is also cost-effective and validated in current CRC screening guidelines, into account.
In our study, risk factors related to colorectal neoplasia were extensively reviewed and evaluated to establish a modified screening model for CRC. The prevalence of ACN in the derivation set and the validation set were 4.1% and 3.7%, respectively, which were generally consistent with previous findings[20, 29–32]. In previous research, the contributions of age, gender, smoking, drinking, family history, diabetes, diet and exercise[17–19, 33–37] have been recognized as major risk factors for CRC. Based on data analysis in this study, the final risk score incorporated age, family history, smoking, alcohol consumption, diabetes and BMI as factors (Table 3). According to this modified score, the HR cohort in the validation set exhibited a 3.4-fold (95% CI 1.8–6.4) increased risk than the AR cohort for ACN. The C-statistic for the modified risk score was 0.69 ± 0.04, slightly higher than that for the original APCS system. Overall, the modified APCS score showed good discrimination and screening effect through data validation. Notably, our modified score assigned a factor age ≥70 with five points, which was higher than the original APCS score, which assigned an age of 50–69 with two points and an age of ≥70 with three points, and our study defined two tiers of risk instead of the three in the original score. The weight of factors came from the univariate and multivariate data analysis of our study, and the cut-off value of the two risk tiers was defined via the analysis of the ROC curve in convenience of developing a practical CRC screening strategy in China. Our modified score recommends that an asymptomatic subject is categorized as a high-risk tier for CRC if he is ≥70 years old or has one of these factors, including 59–69 years old, a CRC family history and a past history of diabetes mellitus with any other risk factors, or is overweight with a habit of smoking and drinking. Overall, the modified score is more efficient and simpler than the original score. For example, based on the original score, a patient ≥70 years of age is assigned 3 points and defined as moderate risk (2–3 points), but it is actually difficult to decide for this individual whether to undergo further screening. In contrast, the two tiers of risk avoid such embarrassment in regard to practical implementation. Compared to the original score, we introduced diabetes as a key risk factor with 2 points, alcohol consumption with 1 point and BMI with 1 point. In addition, sex and other targeted risk factors were left out of our modified score because sex showed significance only for colorectal neoplasia but not
for ACN, and other factors remained nonsignificant for both. The incorporation of diabetes and alcohol consumption into the score system was in accordance with previous study results\(^{10,11}\). BMI has long been recognized as a risk factor for CRC\(^{12}\), and current studies suggest that there is a moderate association between general obesity (as determined by BMI) and the incidence and mortality of CRC and colorectal adenoma\(^{38}\). Similarly, several studies have recently worked on modifying the APCS score by adding BMI for the prediction of advanced neoplasia and reported satisfying discrimination efficiency outcomes\(^{24,39,40}\). Therefore, it is reasonable to incorporate BMI into the CRC prediction and screening questionnaire. Sex is another definite risk factor for CRC, but it failed to show a significant difference in our modeling process. It has been reported that men have an increased risk for advanced neoplasia compared with women, and this positive association was significant across all age groups from age 40 to older than 70 years\(^{41}\), but it was affected by cancer site, diet, menopausal status and so on\(^{42}\). The confounding influence may account for the failure of adding sex into our new score model. Similar situations exist with the association of diet or exercise with ACN. Therefore, it is advisable to detail the questionnaire items and unify the evaluation criteria to further test the relationship of sex, diet, and exercise with the occurrence of ACN.

In recent years, studies have been investigating the combined use of the prediction score with FOBT for raising the screening efficiency of the high-risk cohort for ACN. As reported, the combined use of the APCS score and immunochemical FOBT could correctly instruct 70.6% subjects with ACN and 95.1% subjects with CRC for early colonoscopy examination, thus substantially optimizing medical resources\(^{43}\). In our study, the sensitivity and NPVs of combining the modified score with immunochemical FOBT for predicting ACN were higher than those of using either alone, and the combination of these two economical and simple tests can detect the majority of ACN cases as well as CRC. Thus, in our conceptual CRC screening algorithm (Figure 2), the asymptomatic Chinese subjects should first fill out the risk score questionnaire, and those categorized as AR tiers are then referred for FOBT. Finally, colonoscopy is highly recommended for those in the HR tier or in the AR tier but with positive FOBT. The entire screening path can triage people for colonoscopy in a more effective way.
than the traditional screening strategy, which reduces the workload and optimizes the medical resources of ACN screening for clinical practitioners and government policymakers, especially in vast developing countries such as China.

Some limitations exist in this study. First, most of the data were collected through questionnaire by means of self-reporting, so it is possible to misestimate some risk factors. For example, for the risk factor for diabetes, patients with self-knowledge of diabetes may be lower than the actual prevalence of diabetes, and the estimate of diet may be quite subjective, resulting in bias. Second, the participants in the derivation and validation cohorts mainly came from hospitals in Beijing and Chongqing without covering other parts of China and even other countries in the Asia-Pacific area. Third, except for the targeted risk factors of CRC, we did not compare more detailed information, such as cancer site, pathological types, or quantity of alcohol intake or collected other population characteristics such as menopause status in women and cholecystectomy history. Fourth, due to practical influence, only part of the validation cohort (742 out of 1201 participants) received FOBT, partially causing selection bias in evaluating the efficiency of the combined use of the modified score and FOBT.

In summary, our study established a modified APCS score based on age, BMI, family history, diabetes, smoking and drinking and indicated that its use combined with FOBT is efficient in selecting a high-risk group for CRC from a Chinese asymptomatic population to decrease the workload and optimize the resources of CRC screening for clinical practitioners and government policymakers.

Declarations

**Ethics approval and consent to participate**

This study has been approved by the Ethical Committee of Peking Union Medical College Hospital. The registration number on “Chinese Clinical Trial Registry” was ChiCTR-SOD-16008774. All study participants provided informed written consent prior to study enrollment.

**Consent to publish**

Not applicable.

**Availability of data and materials**
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests / Funding**

Declaration of personal interests: None declared.

Declaration of funding interests: Supported by the National Natural Science Foundation of China (Grant No. 81770559, 81370500) and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2016-12M-3-001).

**Authors' Contributions**

Author contribution: X.H. and S.Y. did the study concept and design, analysis and interpretation of data, and drafting of the manuscript. X.H., W.L., H.Y., W.J., Z.W., J.H., C.C., W.C., Y.G., L.L., and J.Q., did the acquisition of data. K.C. and L.W. did the biostatistics support. J. L. supervised the study. All authors approved the final version of this manuscript.

**Acknowledgements**

Not applicable.

**References**

1Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. Ca-Cancer J Clin, 2018, 68(6): 394–424.

2Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014 [J]. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2018, 30(1): 1–12.

3Tsoi K K F, Ng S S M, Leung M C M, et al. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia [J]. Aliment Pharm Ther, 2008, 28(3): 353–63.

4Benson V S, Atkin W S, Green J, et al. Toward standardizing and reporting colorectal cancer screening indicators on an international level: The international colorectal cancer screening network [J]. Int J Cancer, 2012, 130(12): 2961–73.

5Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): An update [J]. American Journal of Gastroenterology,
6Benard F, Barkun A N, Martel M, et al. Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations [J]. World J Gastroentero, 2018, 24(1): 124–38.

7Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer [J]. Brit J Surg, 2008, 95(8): 1029–36.

8Shaukat A, Mongin S J, Geisser M S, et al. Long-Term Mortality after Screening for Colorectal Cancer [J]. New Engl J Med, 2013, 369(12): 1106-14.

9Yeoh K G, Ho K Y, Chiu H M, et al. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects [J]. Gut, 2011, 60(9): 1236–41.

10Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis [J]. Digestive diseases and sciences, 2012, 57(6): 1576–85.

11Cho E, Smith-Warner S A, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies [J]. Annals of internal medicine, 2004, 140(8): 603-13.

12Wong M C, Lam T Y, Tsoi K K, et al. Predictors of advanced colorectal neoplasia for colorectal cancer screening [J]. American journal of preventive medicine, 2014, 46(5): 433–9.

13Sung J J, Chan F K, Leung W K, et al. Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy [J]. Gastroenterology, 2003, 124(3): 608–14.

14Soon M S, Kozarek R A, Ayub K, et al. Screening colonoscopy in Chinese and Western patients: a comparative study [J]. Am J Gastroenterol, 2005, 100(12): 2749–55.

15Chiu H M, Wang H P, Lee Y C, et al. A prospective study of the frequency and the topographical distribution of colon neoplasia in asymptomatic average-risk Chinese adults as determined by colonoscopic screening [J]. Gastrointest Endosc, 2005, 61(4): 547–53.

16Consultation W. Obesity: Preventing and managing the global epidemic - Introduction [J]. Who Tech Rep Ser, 2000, 894(1-253).
17Imperiale T F, Wagner D R, Lin C Y, et al. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer [J]. Ann Intern Med, 2003, 139(12): 959–65.

18Driver J A, Gaziano J M, Gelber R P, et al. Development of a risk score for colorectal cancer in men [J]. Am J Med, 2007, 120(3): 257–63.

19Lin O S, Kozarek R A, Schembre D B, et al. Risk stratification for colon neoplasia: Screening strategies using colonoscopy and computerized tomographic colonography [J]. Gastroenterology, 2006, 131(4): 1011–9.

20Yeoh K G, Ho K Y, Chiu H M, et al. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects [J]. Gut, 2011, 60(9): 1236–41.

21Wei-Munji E M, De Chavez B T, Lapus I A. The accuracy of Asia Pacific Colorectal Screening Score (APCS) as a risk prediction score for advanced colorectal neoplasia in asymptomatic patients in Cardinal Santos Medical Center (CSMC) for years 2015-2017: A retrospective study [J]. J Gastroen Hepatol, 2018, 33(513-.

22Tsoi K F, Hirai H W, Luk A K, et al. Asia-Pacific colorectal screening (APCS) score is useful for the detection of advanced colonic neoplasm in an asymptomatic population [J]. J Gastroen Hepatol, 2010, 25(A142-A.

23Quach D T, Hiyama T, Nguyen T A, et al. Asia-Pacific Colorectal Screening score: A useful tool to stratify risk for colorectal advanced neoplasms in Vietnamese patients with irritable bowel syndrome [J]. J Gastroen Hepatol, 2018, 33(1): 150–5.

24Sung J J Y, Wong M C, Tsoi K K. Modified Asia-Pacific Colorectal Screening (APCS) Score to Stratify Risk for Colorectal Advanced Neoplasia in Asymptomatic Population in Asian Subjects [J]. Gastroenterology, 2014, 146(5): S730-S.

25Lubis M Y, Abdullah M, Syam A F, et al. The probability of colorectal cancer finding in symptomatic patients using component elements of APCS (Asia Pacific colorectal screening) [J]. J Gastroen Hepatol, 2014, 29(257-.

26Lee S E, Wong R, Cheong W K, et al. Utility of the Asia Pacific Colorectal Screening score in
prioritizing screening colonoscopies for asymptomatic subjects [J]. J Gastroen Hepatol, 2014, 29(257-.
27Wong M, Chen P, Yuan X Q, et al. Validation of the Asia Pacific Colorectal Screening (Apacs) Score and Its Modified Version in Prediction of Advanced Colorectal Neoplasia in Chinese Asymptomatic Subjects [J]. Gut, 2018, 67(A54-A5.
28Corte C, Zhang L, Chen J, et al. Validation of the Asia Pacific Colorectal Screening (APCS) score in a western population. An alternative screening tool [J]. J Gastroen Hepatol, 2015, 30(33-.
29Li W B, Zhang L L, Hao J Y, et al. Validity of APCS score as a risk prediction score for advanced colorectal neoplasia in Chinese asymptomatic subjects: A prospective colonoscopy study [J]. Medicine, 2016, 95(41):
30Sung J J Y, Chan F K L, Leung W K, et al. Screening for colorectal cancer in Chinese: Comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy [J]. Gastroenterology, 2003, 124(3):
608–14.
31Chin H M, Wang H P, Lee Y C, et al. A prospective study of the frequency and the topographical distribution of colon neoplasia in asymptomatic average-risk Chinese adults as determined by colonoscopic screening [J]. Gastrointest Endosc, 2005, 61(4): 547-53.
32Soon M S, Kozarek R A, Ayub K, et al. Screening colonoscopy in Chinese and Western patients: A comparative study [J]. American Journal of Gastroenterology, 2005, 100(12): 2749–55.
33Tsong W H, Koh W P, Yuan J M, et al. Cigarettes and alcohol in relation to colorectal cancer: the Singapore Chinese Health Study [J]. Brit J Cancer, 2007, 96(5): 821–7.
34Sehdev A, O'Neil B H. The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer [J]. Curr Treat Option On, 2015, 16(9):
35Otani T, Iwasaki M, Yamamoto S, et al. Alcohol consumption, smoking, and subsequent risk of colorectal cancer in middle-aged and elderly Japanese men and women: Japan public health center-based prospective study [J]. Cancer Epidem Biomar, 2003, 12(12): 1492–500.
36Deng L Y, Gui Z F, Zhao L Y, et al. Diabetes Mellitus and the Incidence of Colorectal Cancer: An Updated Systematic Review and Meta-Analysis [J]. Digest Dis Sci, 2012, 57(6): 1576–85.
37Larsson S C, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis [J]. J
Natl Cancer I, 2005, 97(22): 1679-87.

38Bardou M, Barkun A N, Martel M. Obesity and colorectal cancer [J]. Postgrad Med J, 2013, 89(1055): 519-33.

39Sekiguchi M, Kakugawa Y, Matsumoto M, et al. A scoring model for predicting advanced colorectal neoplasia in a screened population of asymptomatic Japanese individuals [J]. Journal of Gastroenterology, 2018, 53(10): 1109-19.

40Sung J J Y, Wong M C S, Lam T Y T, et al. A modified colorectal screening score for prediction of advanced neoplasia: A prospective study of 5744 subjects [J]. J Gastroen Hepatol, 2018, 33(1): 187-94.

41Nguyen S P, Bent S, Chen Y H, et al. Gender as a Risk Factor for Advanced Neoplasia and Colorectal Cancer: A Systematic Review and Meta-analysis [J]. Clin Gastroenterol H, 2009, 7(6): 676-81.

42Jacobs E T, Thompson P A, Martinez M E. Diet, gender, and colorectal neoplasia [J]. Journal of Clinical Gastroenterology, 2007, 41(8): 731-46.

43Chiu H M, Ching J Y L, Wu K C, et al. A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms [J]. Gastroenterology, 2016, 150(3): 617-+.

Tables

| Table 1 Characteristics of the derivation and validation cohorts |
|---------------------------------------------------------------|
| **Derivation cohort** n=955                                   | **Validation cohort** n=1201 |
| Age, y, median ± SD                                          | 53.5 ± 8.3                   | 50.7 ± 11.4                   |
| Sex, male, n (%)                                             | 518 (54.2)                   | 743 (61.9)                   |
| BMI, kg/m², median ± SD                                      | 24.3 ± 3.6                   | 24.6 ± 4.3                   |
| Current or ex-smoking, n (%)                                 | 303 (31.7)                   | 370 (30.8)                   |
| Alcohol consumption, n (%)                                   | 452 (47.3)                   | 391 (32.6)                   |
| Diabetes, n (%)                                              | 38 (4.0)                     | 128 (10.7)                   |
| Family history, n (%)                                        | 87 (9.1)                     | 71 (5.9)                     |
| Diet, n (%)                                                  | NA                           | NA                           |
| Vegetable                                                    | 333 (34.9)                   | NA                           |
| Meat                                                         | 187 (19.6)                   | NA                           |
| Unspecific                                                    | 435 (45.5)                   | NA                           |
| Exercise, little, n (%)                                      | 833 (87.2)                   | NA                           |
| Fecal occult blood, n (%)                                     | NA                           | 742†                         |
| Positive                                                     | 117 (15.8)                   | 625 (84.2)                   |
| Negative                                                     | 616 (85.2)                   | NA                           |
| Colorectal neoplasia, n (%)                                   | 197 (20.6)                   | 383 (31.9)                   |
| Colorectal cancer, n (%)                                      | 5 (0.5)                      | 10 (0.8)                     |
| Advanced neoplasia, n (%)                                     | 39 (4.1)                     | 45 (3.7)                     |

NA: not applicable. SD: standard deviation. BMI: body mass index.

† Only 742 subjects in the validation set received FOBT due to practical factors.
Table 2 The relationship between various risk factors and advanced colorectal neoplasia

| Risk factors     | Unadjusted OR (95% CI) | P value | Adjusted OR (95% CI) | β coefficient | SE | OR (95% CI) |
|------------------|-------------------------|---------|-----------------------|---------------|----|-------------|
| Sex              | 1.5 (0.8-3.0)           | 0.207   | -                     | -             |    | -           |
| Age              |                         |         |                       |               |    |             |
| 40-58 Referent   |                         |         |                       |               |    |             |
| 59-69            | 1.4 (0.7-3.0)           | 0.081   | 1.062 (0.384)         | 2.9 (1.4-6.1) |    |              |
| ≥70              | 5.2 (1.8-15.1)          | 0.001   | 2.278 (0.542)         | 9.8 (3.4-28.2)|    |              |
| Family History   | 2.3 (1.0-5.4)           | 0.050   | 0.921 (0.454)         | 2.5 (1.0-6.1)|    |              |
| Smoking          | 2.4 (1.2-4.5)           | 0.007   | 0.572 (0.395)         | 1.8 (0.8-3.8)|    |              |
| Alcohol consumption | 2.0 (1.0-4.0)       | 0.032   | 0.744 (0.429)         | 2.1 (0.9-4.9)|    |              |
| Diabetes         | 3.9 (1.5-10.7)          | 0.004   | 1.242 (0.536)         | 3.5 (1.2-9.9)|    |              |
| BMI ≥ 23         | 2.2 (1.0-4.8)           | 0.046   | 0.759 (0.422)         | 2.1 (0.9-4.9)|    |              |
| BMI ≥ 25         | 1.4 (0.8-2.7)           | 0.262   | -                     | -             |    |              |
| BMI ≥ 28         | 0.8 (0.3-2.4)           | 0.756   | -                     | -             |    |              |
| Diet             |                         |         |                       |               |    |             |
| Vegetable        | 1.2 (0.6-2.3)           | 0.631   | -                     | -             |    |              |
| Meat             | 1.1 (0.5-2.4)           | 0.881   | -                     | -             |    |              |
| Exercise         | 0.9 (0.4-2.4)           | 0.868   | -                     | -             |    |              |

OR: odds ratio. SE: standard error. CI: confidence interval. BMI: body mass index.

Table 3 The final risk scores for screening of advanced colorectal neoplasia in Chinese population

| Risk Factors          | Criteria        | Points |
|-----------------------|-----------------|--------|
| Age                   |                 |        |
| <59                   |                 | 0      |
| 59-69                 |                 | 2      |
| ≥70                   |                 | 5      |
| Family history        |                 |        |
| Absent                |                 | 0      |
| Present               |                 | 2      |
| Smoking               |                 |        |
| Never                 |                 | 0      |
| Current or past       |                 | 1      |
| Drinking              |                 |        |
| Never                 |                 | 0      |
| Current or past       |                 | 1      |
| Diabetes              |                 |        |
| Absent                |                 | 0      |
| Present               |                 | 2      |
| BMI                   |                 |        |
| < 23                  |                 | 0      |
| ≥ 23                  |                 | 1      |

BMI: body mass index.

Table 4 Stratification of the prevalence of advanced colorectal neoplasia by risk tier

| Risk tier | Derivation set | Validation set |
|-----------|----------------|----------------|
|           | Number (%)     | Number (%)     | Neoplasia (%) |
|           | ACN (%) (95% CI)| ACN (%) (95% CI)| (95% CI)     |
| AR (0-2)  | 541 (56.6)     | 743 (61.9)     | 167 (22.5)   |
|           | 10 (1.8) (0.7- 3.0)| 15 (2.0) (1.0- 3.0)| (19.5-25.5)| |
| HR (≥3)   | 414 (43.4)     | 458 (38.1)     | 216 (47.2)   |
|           | 29 (7.0) (4.5- 9.5)| 30 (6.6) (4.3- 8.8)| (42.6-51.8)| |
| Total     | 955 (100)      | 1201 (100)     | 383 (31.9)   |
|           | 39 (4.1) (2.8- 5.1)| 45 (3.7) (2.7- 4.8)| (29.3-34.5)| |

ACN: advanced colorectal neoplasia. OR: odds ratio. CI: confidence interval. AR: average risk. HR: high
Table 5 Fecal occult blood test distribution in the validation set

|                | ACN                  | Advanced adenoma | CRC | Nonadvanced neoplasia | Negative | Total |
|----------------|----------------------|------------------|-----|-----------------------|----------|-------|
|                | n (%)                | OB- (%)          | OB+ (%) | n (%)                | OB- (%) | OB+ (%) | Se-1 (%) | Se-2 (%) | Se-3 (%) |
| AR (0-2)       | 9 (2.1)              | 7 (2.1)          | 2 (4.6) | 64 (15.1)            | 52 (80.7) | 110 (31.6) | 76.7% | 36.7% | 72.0% | 28.0% | 70.1% | 14.4% |
| HR (≥3)        | 21 (6.0)             | 12 (6.0)         | 9 (4.0) | 110 (31.6)           | 97 (31.6) | 13 (4.0) | 76.7% | 36.7% | 72.0% | 28.0% | 70.1% | 14.4% |
|                |                      |                  |      |                       |          |       |        |        |        |        |        |        |
| Se-1† (%)      |                     |                  |      |                       |          |       |        |        |        |        |        |        |
| Se-2† (%)      |                     |                  |      |                       |          |       |        |        |        |        |        |        |
| Se-3† (%)      |                     |                  |      |                       |          |       |        |        |        |        |        |        |

ACN: advanced colorectal neoplasia. CRC: colorectal cancer. AR: average risk. HR: high risk. OB: occult blood test. NPV: negative predictive value.

†Se-1~3: sensitivity of the modified APCS score combined with fecal occult blood test (Se-1), of fecal occult blood test alone (Se-2), and of the modified APCS score alone (Se-3) for screening high risk cohorts for colonoscopy.

‡NPV-1~3: NPV of the modified APCS score combined with fecal occult blood test (NPV-1), of fecal occult blood test alone (NPV-2), and of the modified APCS score alone (NPV-3) for screening high risk cohorts for colonoscopy.
Figure 1

Flowchart demonstrating the process for the validation set. APCS: the Asia-Pacific Colorectal Screening score. AR: average risk. HR: high risk. FOBT: fecal occult blood test. AA: advanced adenoma. ACN: advanced colorectal neoplasia. CRC: colorectal cancer.
Figure 2

Conceptual colorectal cancer screening algorithm of APCS score combined with FOBT. APCS: the Asia-Pacific Colorectal Screening score. AR: average risk. HR: high risk. FOBT: fecal occult blood test.